姓名：邹争志
学历：博士
职称：副教授
职务：科研教学
研究方向：肿瘤分子靶向治疗
联系电话：-8404
电子邮箱：zouzhengzhi@scnu.edu.cn
通讯地址：广州天河区中山大道西55号华南师范大学生物光子学研究院（510631）
个人主页：-

个人简历
发表论文
出版著作
科研项目
主要获奖
会议论文
个人空间



邹争志，博士，硕导，华南师范大学生物光子学研究院副教授，国家生物医学工程学会会员、广东省光学学会会员，广东省科技企业科技特派员。国家自然科学基金通讯评审专家、捷克自然科学基金通讯评审专家、广东省科技发展专项资金项目库专家。近五年主持国家自然科学基金3项、广东省自然科学基金2项、广州市科技计划项目、教育厅青年创新人才类项目（自然科学类）和华南师范大学优秀青年教师科研培育基金等项目，作为骨干成员参与国家重大科研仪器专项，国家自然科学基金国际(地区)合作与交流项目、国家自然科学基金重点项目。申请发明专利4项，获发明专利1项。研究方向：肿瘤分子靶向治疗与免疫治疗。担任Oncogene、theranostics、Breast cancer research、Cell Death&Disease、Cancer letters、BMC cancer等数十种国际SCI杂志审稿人。目前已在SCI收录杂志上发表文章20多篇，其中第一作者或通讯作者22篇。文章他引次数700多次，单篇最高131次。





教育经历：
2008.9-2011.6中山大学肿瘤防治中心，华南肿瘤学国家重点实验室，博士
2005.9-2008.6江西农业大学动物生物技术国家重点实验室，硕士
2001.9-2005.6湖南科技大学，生命科学学院，本科，学士学位


工作经历：
2012.9-2016.12 华南师范大学，生物光子学研究院，讲师
2016.12-至今 华南师范大学，生物光子学研究院，副研究员,硕导



发表论文：（IF为发表当年影响因子）
第一作者或通讯作者SCI论文


1. Yibing Chen1#*, Yucen Song1#, Yanjun Mi2#, Huan Jin, Jun Cao, Haolong Li, Liping Han, Ting Huang, Xiaofei Zhang, Lingyi Che, Zhihui Jiao, Shumin Ren, Qian Ma, Xu Gao, Zhengzhi Zou*. microRNA-499a promotes the progression and chemoresistance of cervical cancer cells by targeting SOX6. Apoptosis. 2020 Jan 14. (corresponding author, IF:4.921 生物2区)
2. Hai Hu, Wenzhi Tu, Yungu Chen, Ming Zhu, Zhengzhi Zou*, Qing Xia*. Tumor-Associated Macrophages: an accomplice in solid tumor progression. Journal of Cancer 2020 Jan. (corresponding author, IF: 3.182 医学3区)
3. Longlong Gong, Yingyao Quan, Zhengzhi Zou* Rosiglitazone ameliorates skeletal muscle insulin resistance by decreasing free fatty acids release from adipocytes. Artificial Cells, Nanomedicine and Biotechnology 2020 in press. (corresponding author, IF: 4.462 医学2区)
4. Ni Qiu, Yu-fang He, Si-ming Zhang, Yong-tao Zhan, Guo-dong Han, Ming Jiang, Wei-xing He, Jie Zhou, Hong-ling Liang, Xiang Ao, Hao-ming, Xia, Jia Li, Yu-yang Yang, Zhi-min He, Zheng-zhi Zou*, Hong-sheng Li*. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway. Cancer Letters, 2019 Nov, 464: 25-36 (corresponding author, IF: 6.508, 医学1区)
5. Chen Y, Mi Y, Zhang X, Ma Q, Song Y, Zhang L, Wang D, Xing J, Hou B, Li H, Jin H, Du W*, Zou Z*. Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells. J. Exp. Clin. Cancer Res. 2019 Sep 13;38(1) DOI：10.1186/s13046-019-1413-7 (corresponding author, IF: 5.646, 医学2区)
6. Yibing Chen^*, Yucen Song, Wei Du, Longlong Gong, Haocai Chang, Zhengzhi Zou^* Tumor-Associated Macrophages: an accomplice in solid tumor progression. Journal of biomedical science 2019 Oct 20;26(1). (corresponding author, IF: 5.203 医学2区)
7. Longlong Gong, Shuang Guo, Zhengzhi Zou* Resveratrol ameliorates metabolic disorders and insulin resistance in high-fat diet-fed mice. Life Sciences, 2019 Dec (corresponding author, IF: 3.244, 生物3区)
8. Songmao Wang, Zhengzhi Zou*, Haocai Chang and Da Xing*. LRH1 enhances breast cancer cells chemoresistance by activating MDC1 to attenuate DNA damage. Oncogene 2018 Jun;37(24):3243-3259. doi: 10.1038/s41388-018-0193-4 (corresponding author, IF: 6.854 医学1区)
9. Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis. 2017 Sep 21. doi: 10.1007/s10495-017-1424-9. (corresponding author, IF: 3.833 生物2区)
10. Chen P, Luo X, Nie P, Wu B, Xu W, Shi X, Chang H, Li B, Yu X, Zou Z*. CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk. Free Radic Biol Med. 2017 25;104:280-297. (corresponding author, IF: 6.020，医学2区)
11. Zhu J, Zou Z*, Nie P, Kou X, Wu B, Wang S, Song Z* and He J*. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Cell Death Dis. 2016;7:e2454. (co-first and corresponding author, IF: 5.638，生物2区)
12. Ao X, Nie P, Wu B, Xu W, Zhang T, Wang S, Chang H, Zou Z*. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis. 2016；7(11):e2463. doi: 10.1038/cddis.2016.367. (corresponding author, IF: 5.638，生物2区)
13. Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, Tang Z, Zhu Y, Chen S, Xu J, Yan M, Wang J, Liu Q*. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy. 8: 1798-1810. 2012. (IF: 12.042，生物1区)
14. Xiaoyong Luo,Jinke Yao, Peipei Nie, Zhiyuan Yang, Hongbo Feng, Pinjia Chen, Xinpeng Shi,Zhengzhi Zou*. FOXM1 promotes invasion and migration of colorectal cancer cells partially dependent on HSPA5 transactivation. Oncotarget. 2016. May 3;7(18):26480-95. (corresponding author, IF: 5.008)
15. Zheng-Zhi Zou, Pei-Pei Nie, Ya-Wei Li, Ben-Xin Hou, Rui-Li, Xin-Peng Shi, Zhao-Kui Ma, Bao-Wei Han, Xiao-Yong Luo*. Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. Oncotarget. 2017 Apr 4;8(14):22414-22432. (IF: 6.359)
16. Peipei Nie, Weicheng Hu, Tao Zhang, Yiju Yang, Benxin Hou, Zhengzhi Zou*. Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non–Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA. Cellular Physiol Biochem 2015; 1421-9778/15/0351-0001 (corresponding author, IF: 4.655)
17. Zhengzhi Zou*, Xiaoyong Luo, Peipei Nie, Baoyan Wu, Tao Zhang, Yanchun Wei, Wenyi Wang, Guojun Geng, Jie Jiang, Yanjun Mi*. Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2016; 9;478(1):227-33. (corresponding author, IF: 2.371)
18. Jiang S, Zou Z, Nie P, Wen R, Xiao Y, Tang J. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells. PLoS One 2015;10(7):e132880. (co-first author, IF: 3.23)
19.Yan-jun Mi , Guo-jun Geng, Zheng-zhi Zou, Jing Gao, Xian-yang Luo, Yu Liu, Ning Li, Chun-lei Li, Yu-Qiang Chen, Xiu-yi Yu, Jie Jiang. Dihydroartemisinin Inhibits Glucose Uptake and Cooperates with Glycolysis Inhibitor to Induce Apoptosis in Non-Small Cell Lung Carcinoma Cells. PLoS ONE. 10(3):e**. doi: 10.1371/journal.pone.**. 2015 (co-first author, IF: 3.73)
20. Jing Gao, Zhengzhi Zou, Jing Gao, Haifang Zhang, Zhicai Lin, Yaya Zhang, Xianyang Luo, Changhua Liu, Jingdun Xie, Chengfu Cai. Increased expression of HMGB3: a novel independent prognostic marker of worse outcome in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2015;8(1):345-352 (co-first author, IF: 1.783 2.052)
21. Lou Y, Zou Z, Chen P, Huang G, Li B, Zheng D, Yu X, Luo X. Combination of Gefitinib and DNA Methylation Inhibitor Decitabine Exerts Synergistic Anti-Cancer Activity in Colon Cancer Cells. PLoS ONE. 9(5): e97719. doi:10.1371/journal.pone.**. 2014 (co-first author, IF: 3.73)
22. Zou Z, Ren J, Yan X, Huang X, Yang S, Zhang Z, Yang B, Li W, Huang L*. Quantitative trait loci for porcine baseline erythroid traits at three growth ages in a White Duroc x Erhualian F2 resource population. Mammalian Genome. 19, 640-646. 2008. (IF: 2.419)





主持和参与项目：
1.国家自然科学基金-面上项目：乳腺癌化疗耐药细胞激活NCOA3促进巨噬细胞M2型极化诱导癌细胞转移的作用与机制。（**）直接经费：55万，主持 2020.01-2023.12
2.国家自然科学基金-面上项目：NR5A2上调MDC1促进DNA损伤修复增强乳腺癌化疗耐药研究（**）直接经费：60万， 主持 2018.01-2021.12
3.国家自然科学基金-青年科学基金项目（**）：在靶向Aurora-A治疗乳腺癌中自噬的作用及其诱导机制研究 23万，主持 2015
4.MAPK4介导的巨噬细胞M2极化在宫颈癌恶性进展中的作用机制 (2019A)。10万，主持 起止年月：2019-10-1至2022-9-30
5. LRH1促进糖酵解增强NSCLC对EGFR-TKI耐药的研究 广州市科学研究计划一般项目（广州市科技计划项目-科学研究一般项目8） 20万，主持 2019/4/1-2022/3/31
6.广东省自然科学基金-博士启动基金项目（2014A）：自噬在Aurora A诱导乳腺癌形成中的作用与机制 10万，主持 2015
7.2014年广东省教育厅青年创新人才类项目（自然科学类）：靶向Aurora-A治疗乳腺癌中自噬增强癌细胞凋亡抵抗的分子机制研究 3万，主持2015
8.华南师范大学优秀青年教师培育基金（自然科学类）：硫链丝菌素诱导乳腺癌内质网应激的作用与机制研究 3万，主持 2014
9.国家自然科学基金重大科研仪器研制项目：定量FRET显微成像仪的研制(**)，研究总经费510.32万元，直接经费442.1万元，起止年月：2016.01-2020.12 （参与，排名第三）
10. 国家自然科学基金-重点项目：微波-光声多参数早期乳腺肿瘤特异性分子成像新技术研究，直接经费275万元，起止年月：2017-1-1至2021-12-31 （参与，排名第六）



2008年获中国畜牧兽医学会优秀论文奖。